We are dedicated to developing better medicines for patients and have drug candidates in development across a range of diseases.

Our Research and Development strength is our deep understanding of established hormonal biology. This provides leverage to identify a host of novel approaches to target hormone receptors in serious medical conditions where we can develop and commercialize new medicines.

This focus has led to a pipeline of clinical and preclinical product candidates that target and modulate various hormone receptors and have the potential to treat a variety of oncologic, urologic, endocrine, wasting and inflammatory diseases.

Our lead disease program targets patients with two different, well defined types of breast cancer; Estrogen receptor positive (ER+) disease as well as triple negative breast cancer (TNBC). We plan to study the androgen receptor positive (AR+) patients in these two diverse breast cancer groups and Phase 2 clinical trials are underway.

This same understanding of the hormone balance in health and disease has led us to evaluate the effects of androgen modulation in postmenopausal women with stress urinary incontinence. Other earlier stage programs that have come from our understanding of hormonal effects include Duchenne muscular dystrophy and castration-resistant prostate cancer.